European Scientific Working Group on Influenza (ESWI) Conference December 6, 2021 Supporting Materials Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose 914.7 KB Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 - preliminary report of a phase 2a, open-label, single dose escalation study 773.1 KB
Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose 914.7 KB
Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 - preliminary report of a phase 2a, open-label, single dose escalation study 773.1 KB